← Back to all signals
RESEARCH PAPER ANALYSIS

CycleGAN models show consistent brain MRI synthesis across datasets supporting downstream tissue characterization in multiple sclerosis.

This paper evaluates CycleGAN and Pix2Pix models to synthesize missing T1/T2 brain MRI across HCP, PPMI and an MS cohort, showing Pix2Pix often outperforms CycleGAN and that synthesized T1 images can be used for lesion detection, volumetry, and texture analysis in MS.

PMID41908698
JournalFrontiers in neuroinformatics
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This paper evaluates CycleGAN and Pix2Pix models to synthesize missing T1/T2 brain MRI across HCP, PPMI and an MS cohort, showing Pix2Pix often outperforms CycleGAN and that synthesized T1 images can be used for lesion detection, volumetry, and texture analysis in MS.

WHY IT MATTERS

Research significance

Direct therapeutic relevance to Parkinson's is limited, but the demonstrated ability to synthesize missing MRI contrasts (validated on PPMI data) can help recover incomplete imaging datasets and enable quantitative biomarker or longitudinal imaging studies in PD research.

ABSTRACT

Source abstract

BACKGROUND: Secondary quantitative analysis of brain magnetic resonance imaging (MRI) can provide valuable information for many neurological diseases, including multiple sclerosis (MS), but it demands complete datasets that are often unavailable clinically. We investigated how image synthesis via deep learning using cycle-consistent generative adversarial networks (CycleGANs) compared with Pix2Pix as a related method, based on T1-weighted and T2-weighted brain MRI in MS, following verification on two streamlined datasets. The synthesized images were also evaluated against the source data. METHODS: The streamlined datasets involved 1,113 healthy participants from the Human Connectome Project (HCP) and 318 participants from the Parkinson's Progression Markers Initiative (PPMI). The MS cohort in this study included 105 participants scanned with different protocols. Image synthesis was bidirectional between T1- and T2-weighted MRI using CycleGAN with and without spectral normalization, as well as Pix2Pix. Utility testing focused on T1-weighted MRI that was most often unavailable in MS, and that involved lesion detection, brain volumetry, and lesion texture analysis. RESULTS: All CycleGAN models performed competitively, while Pix2Pix performed better, mostly with streamlined datasets (p < 0.001). The average peak signal-to-noise ratio ranged from 24.860-28.570 versus 28.520-31.100, and the structural similarity index ranged from 0.838-0.901 versus 0.924-0.943. With spectral normalization, CycleGAN improved in PPMI but not in HCP and generally not in MS (p < 0.001). Furthermore, the synthesized images showed high similarity to the source data in utility tests, although Pix2Pix T1 images appeared more heterogeneous in lesion texture than source T1 images. CONCLUSION: CycleGAN without spectral normalization appeared feasible for synthesizing common clinical brain MRI, including T1-weighted images usable for subsequent quantitative analysis in MS.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic